Men’s Health Update

Enzalutamide Increases Overall Survival in nmCRPC

Publish Date June 1, 2020

In the PROSPER study, median overall survival was significantly longer among enzalutamide-treated patients compared with placebo recipients (67.0 vs 56.3 months).

Intense Neoadjuvant ADT for High-Risk PCa Improves Pathologic Response

Publish Date May 30, 2020

After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.

PET/CT Imaging Potentially Useful in Evaluating mCRPC Treatment Response

Publish Date May 29, 2020

Almost 40% of men with metastatic castration-resistant prostate cancer experience radiographic disease progression while on second-generation hormone therapy despite stable or declining PSA, a study found.

Relugolix Superior to Leuprolide in Advanced Prostate Cancer

Publish Date May 29, 2020

In the phase 3 HERO trial, more relugolix than leuprolide recipients achieved sustained testosterone suppression over 48 weeks: 96.7% vs 88.8%, respectively.

Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic

Publish Date May 29, 2020

Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.

Only One in Four US Hospitals With ICUs Have Tele-ICU Services

Publish Date May 29, 2020

Wide regional variation seen for availability of telehealth outpatient visits, tele-ICU services.

Factors Linked to COVID-19 In-Hospital Mortality ID’d in NYC

Publish Date May 26, 2020

22% of patients critically ill; older age, chronic cardiac disease linked to higher in-hospital mortality.

HSD3B1 Genotype Tied to Worse Outcomes in Low-Volume mCSPC

Publish Date May 25, 2020

New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.

Local-Stage Prostate Cancer Incidence Rates Continue to Drop

Publish Date May 22, 2020

Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.

Olaparib Approved for Metastatic Castration-Resistant Prostate Cancer

Publish Date May 21, 2020

The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.